title: Open trial of intravenous tissue plasminogen activator in acute carotid territory stroke. Correlations of outcome with clinical and radiological data.
abstract: OBJECTIVE
  Pilot studies using early thrombolytic therapy in stroke have suggested that recombinant tissue plasminogen activator (rTPA) might be effective. While large, double-blind, randomized studies are needed, open trials could generate hypotheses concerning (1) the clinical correlations of outcome, (2) the significance of CT scan data during the first week, and (3) the use of adjunctive therapies.
  
  
  METHODS
  We performed an open trial of intravenous rTPA on patients referred to our emergency service with all types of ischemic stroke in the carotid territory. All patients between 20 and 81 years hospitalized during 1994 with completed stroke in the internal carotid artery territory and a baseline Scandinavian Stroke Scale score lower than 48, even with severe disturbances of consciousness, were included. The inclusion time was within 7 hours after stroke onset. A 0.8-mg/kg dose of rTPA was infused for 90 minutes. Intravenous heparin was given either immediately at efficient dosage or after 24 hours. Mannitol was used in patients with severe presentation. The Scandinavian Stroke Scale evaluation was done at baseline, 3 hours, and 1, 7, 30, and 90 days. The CT scan was performed before the treatment and at days 1 (24 +/- 6 hours) and 7.
  
  
  RESULTS
  Forty-three consecutive patients met the criteria of the protocol. The mean age at inclusion was 65 +/- 10.4 years, and the mean interval to treatment was 232 +/- 79 minutes. At day 90, 25 patients (58.1%) exhibited a complete regression of symptoms, and 3 had moderate neurological sequelae. Thirteen patients had severe neurological sequelae, 11 with infarcts and 2 with secondary parenchymal hematomas. Two patients died (4.6%), 1 with hematoma. The overall hematoma rate was 6.9%. Excellent outcome at day 90 was significantly correlated with major neurological improvement at day 1. Intravenous immediate heparin versus delayed heparin after 24 hours improved the ischemic outcome but not the overall outcome. Reinfarction syndromes after major neurological improvement, likely to be rethrombosis syndromes, were observed in 3 patients (6.9%). For the day 1 CT scan, poor outcome was associated with the presence of structured and homogeneous hypodensities likely to represent classic infarcts, as confirmed by day 7 CT scan. Conversely, total recovery was significantly associated with the absence of any image or with unstructured hypodensities, a particular type of image characterized by its heterogeneous darkness and often polylobar shape. This type of image disappeared at day 7 in 17.6% of the cases and is likely to represent reperfusion images and/or incomplete ischemic damage.
  
  
  CONCLUSIONS
  The results obtained in this open, small study suggest safety and effectiveness of rTPA thrombolysis at the dose of 0.8 mg/kg within 7 hours in acute strokes of the carotid territory, including highly serious baseline neurological presentations, until age 81 years and under special therapeutic conditions. Complete recovery is significantly associated with major neurological improvement during the first 24 hours and the presence of a particular type of image at day 1 CT scan characterized by an unstructured hypodensity, often polylobar and heterogeneous, which is likely to correspond to reperfusion images.
authors.affiliation: Cerebrovascular Unit, Hôpital Neurologique, Lyon, France.
authors.forename: P
authors.initials: P
authors.lastname: Trouillas
authors.forename: N
authors.initials: N
authors.lastname: Nighoghossian
authors.forename: J C
authors.initials: JC
authors.lastname: Getenet
authors.forename: G
authors.initials: G
authors.lastname: Riche
authors.forename: P
authors.initials: P
authors.lastname: Neuschwander
authors.forename: J C
authors.initials: JC
authors.lastname: Froment
authors.forename: F
authors.initials: F
authors.lastname: Turjman
authors.forename: J X
authors.initials: JX
authors.lastname: Jin
authors.forename: D
authors.initials: D
authors.lastname: Malicier
authors.forename: G
authors.initials: G
authors.lastname: Fournier
authors.forename: A L
authors.initials: AL
authors.lastname: Gabry
authors.forename: X
authors.initials: X
authors.lastname: Ledoux
authors.forename: L
authors.initials: L
authors.lastname: Derex
authors.forename: Y
authors.initials: Y
authors.lastname: Berthezène
authors.forename: P
authors.initials: P
authors.lastname: Adeleine
authors.forename: J
authors.initials: J
authors.lastname: Xie
authors.forename: P
authors.initials: P
authors.lastname: Ffrench
authors.forename: M
authors.initials: M
authors.lastname: Dechavanne
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001157:Arterial Occlusive Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D002545:Brain Ischemia / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D002339:Carotid Arteries; D002341:Carotid Artery Thrombosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000401:mortality; D002343:Carotid Artery, Internal; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D015996:Survival Rate; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator